Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Delhi High Court on Wednesday asked Drug Controller General of India (DCGI) to consult experts and relevant stakeholders ...

Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

The US Food and Drug Administration (FDA) has issued an urgent warning about tianeptine—a substance marketed as a dietary ...

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...